Skip to contentL
Lyell Immunopharma, Inc.
L
LYELLyell Immunopharma, Inc. Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$11.00K$11.00Kderived−15.4% vs Q4 2023 Net Income-$191.94M-$191.94MderivedN/M vs Q4 2023 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lyell Immunopharma, Inc. · CIK 1806952 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$201,147,000N/M Operating Cash Flowderived-$47,242,000N/M Free Cash Flowderived-$47,286,000N/M Margins · derivedOperating margin-1828609.1%−1370855.2 pt vs Q4 2023
Net margin-1744863.6%−1337709.8 pt vs Q4 2023
ended Dec 31, 2024 · filed Mar 11, 2025 · 70 d after period end